Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:VVUS

VIVUS (VVUS) Stock Price, News & Analysis

VIVUS logo

About VIVUS Stock (NASDAQ:VVUS)

Key Stats

Today's Range
N/A
50-Day Range
$0.26
$0.47
52-Week Range
N/A
Volume
2.03 million shs
Average Volume
1.44 million shs
Market Capitalization
$7.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Receive VVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

VVUS Stock News Headlines

VIVUS Shares Significant Regulatory Update on QSYMIA®
VIVUS Announces Label Update for QSYMIA®
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
VIVUS Provides Update on Pipeline and Program Milestones
See More Headlines

VVUS Stock Analysis - Frequently Asked Questions

VIVUS, Inc. (NASDAQ:VVUS) issued its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter.

VIVUS's stock reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Novavax (NVAX), CymaBay Therapeutics (CBAY) and Amarin (AMRN).

Company Calendar

Last Earnings
5/06/2020
Today
11/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VVUS
CUSIP
92855110
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-31,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$69.76 million
Book Value
($6.50) per share

Miscellaneous

Free Float
N/A
Market Cap
$7.33 million
Optionable
Optionable
Beta
-0.84
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:VVUS) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners